Quantitation of HER2 and telomerase biomarkers in solid tumors with IgY antibodies and nanocrystal detection
Article first published online: 23 JAN 2008
Copyright © 2008 Wiley-Liss, Inc.
International Journal of Cancer
Volume 122, Issue 10, pages 2178–2186, 15 May 2008
How to Cite
Xiao, Y., Gao, X., Gannot, G., Emmert-Buck, M. R., Srivastava, S., Wagner, P. D., Amos, M. D. and Barker, P. E. (2008), Quantitation of HER2 and telomerase biomarkers in solid tumors with IgY antibodies and nanocrystal detection. Int. J. Cancer, 122: 2178–2186. doi: 10.1002/ijc.23320
- Issue published online: 17 MAR 2008
- Article first published online: 23 JAN 2008
- Manuscript Accepted: 12 OCT 2007
- Manuscript Received: 13 JUL 2007
- NCI-NIST Interagency Agreement. Grant Number: Y1-CN-45016
- NIST HER2 Standard Reference Material development funds. Grant Number: RM 2373
- IgY antibody;
- cancer biomarker;
- quantum dots
In an effort to improve affinity biomarker validation in fixed patient tissue specimens, we have developed a novel quantum dot-based bioimaging system that utilizes chicken IgY antibody for high sensitivity and specificity relative quantitation of cancer proteins. Monospecific, polyclonal IgYs were generated against human HER2 and telomerase, and analytically validated for specificity by western blot and immunohistochemistry on tumor and normal cells and for relative affinity by layered peptide array (LPA). IgYs bound desired targets in cell lines and fixed tissues and showed greater affinity than commercial mammalian antibodies for both HER2 and telomerase proteins. In tissue microarray experiments, HER2 quantitation with IgY antibody and quantum dot imaging correlated well with chromogenic in situ hybridization (CISH), whereas telomerase quantitation suggested a trend toward correlation with prostate cancer Gleason Grade and differentiation. Although patient numbers were small, these findings demonstrate the feasibility of relative quantitation of cancer biomarkers with IgY and quantum dot fluorophores, and show promise for rigorous clinical validation in large patient cohorts. © 2008 Wiley-Liss, Inc.
Few new early cancer biomarkers have surfaced in recent years.1 Among novel proteomic biomarkers for early cancer detection, some have proven controversial.2, 3 Analytical and clinical validation of cancer biomarkers has suffered from bias in the design, conduct and interpretation of such research,4 incompletely validated imaging,5 and lack of affinity standards6 and antibodies that did not, in fact, detect correct targets.7
Here, we describe a novel approach to cell-based bioimaging with relative quantitation for biomarker validation. We report characterization of two new IgY antibodies for quantitation of model cancer biomarker systems, HER2 and telomerase,8 and explore analytical improvements, including low cross-reactivity IgY-isotype chicken polyclonal antibodies raised against recombinant polypeptides; digital quantification of antibody signals with streptavidin-conjugated semiconductor nanocrystals to obviate photobleaching of organic fluorescent dyes; complete z-plane fluorescence image capture using 3D-deconvolution microscopy; high-throughput, automated, robotic slide processing; and quantitative, massively parallel, high-throughput analysis of peptide antigen–antibody interactions by layered peptide array (LPA) technology.9
The data presented here for HER2 and telomerase IgY antibodies in cancer biomarker detection show promise for differentiating patient tumors in tissue microarray (TMA) format from normal control tissues. More generally, these results promise improvements in measuring and standardizing affinity and antibody-based proteomic reagents that may expedite clinical proteomics validation projects for cancer biomarkers.
Material and methods
Protein sequence domains of human HER2 (human epithelial growth factor family receptor-2/neu, GenBank No. NP_004439.1), and human telomerase (hTERT, GenBank No. NP_003210.1) were selected for design of polypeptide immunogens. Polypeptide antigen sequence and design considerations will be reported elsewhere. The anti-HER2 IgY antibody is termed YXPB-IgY-hHER2/p. The anti-telomerase IgY antibody is named YXPB-IgY-hTel/p (Table I). Each resulted from production experiments that generated a single polyclonal antibody lot. Antigens were expressed as recombinant protein and purified from E. coli cells. Immunogens were injected intramuscularly into one laying hen (leghorn/Rhode Island) for each immunogen. About 200 μg of antigen protein were mixed with Complete Freund's Adjuvant (CFA) for primary immunization. Booster inoculations were performed at 2–3 weeks interval with 100 μg antigen in Incomplete Freund's Adjuvant (IFA) for 3 inoculation cycles. Eggs were collected after a second boost. Antibodies were isolated from egg yolk using the polyethylene glycol (PEG) precipitation method.11 The antibodies were further purified by affinity chromatography with immunogen as affinity ligand. Antibody production was performed on contract by GenWay (San Diego, CA).
|Anti-human HER2 Antibodies|
|YXPB-IgY-hHER2/p||1||IgY, chicken polyclonal||Xiao et al., this data|
|AO485||2||IgG, rabbit polyclonal||Dako (Glostrup, Denmark)|
|CB11||3||IgG, mouse monoclonal||Ventana (Tucson, AZ)|
|Anti-human Telomerase Antibodies|
|YXPB-IgY-hTel/p||4||IgY, chicken polyclonal||Xiao et al., this data|
|NCL-hTERT||5||IgG, murine monoclonal||Novocastra (Newcastle upon Tyne, UK)|
|NB100-297||6||IgM, murine monoclonal||Novus (Littleton, CO)|
|Control Antibodies (anti-β-actin)|
|ab13822||7||IgY, chicken polyclonal||Abcam (Cambridge, MA)|
Commercially available primary mammalian antibodies for comparison with IgY antibodies generated here are summarized in Table I together with their antigens and sources. These were chosen as they are the most widely used antibodies in research studies and therefore considered the best available. Secondary antibodies were anti-IgY biotinylated antibody (GenWay), and anti-IgG biotinylated antibody (Ventana). Each was detected by fluorescence microscopy with streptavidin-Qdot605 (Invitrogen, Carlsbad, CA) as the final affinity detection reagent. As a control, chicken IgY isotype antibody ab14001 specific for human β-actin was obtained from Abcam.
Antibody studies on fixed cultured cells
For HER2, human breast cancer cell lines MCF-7 (low HER2 gene copy number and expression) and SK-BR-3 (high HER2 gene copy number and expression) were studied as a model system. For telomerase, human cell lines A549 and IMR90 were the positive and negative control model system studied,12 with high and low telomerase levels, respectively. Cells were grown on tissue culture chamber slides (Nunc, Rochester, NY) in medium as recommended by American Type Culture Collection (Manassas, VA), at a density of 30,000 cells/cm2. Cell monolayers were fixed in 10% neutral-buffered zinc formalin (Fisher, Pittsburgh, PA) but not paraffin-embedded. Fixed monolayers were preblocked with 5% w/v nonfat dry milk in TBST (50 mM Tris-HCl, 150 mM NaCl, 150 mM Tween 20, pH 7.5), 20°C, for 20 min. For antibody detection, slides were manually incubated with primary antibody, secondary antibody and fluorescent detection reagents. Primary antibody dilutions are: IgY 1:300 (final concentration 3.3 μg/ml), CB11 IgG undiluted as per manufacturer instructions (6.0 μg/ml), NCL-hTERT 1:200 (16.5 μg/ml). Alternatively with high-throughput technology, slides were robotically prepared (reaction with primary and secondary antibodies, and washes) with a Benchmark XT workstation (Ventana).13 IgY-isotype antibodies were detected with rabbit anti-IgY antibody labeled with biotin, followed by semiconductor nanocrystal fluorophore-streptavidin conjugates (Invitrogen). FluoSpheres carboxylate-modified microspheres, 0.2 μm, crimson fluorescent (Invitrogen) were used as calibration standard. Imaging systems for 3D analysis of fluorescence signals from quantum dots, deconvolution of z-plane (depth) images, and integration of the signal with an imaging system were described elsewhere.14
Antibody studies in patient and control tissues with tissue microarrays (TMAs)
Tissue microarrays (fixed in 10% neutral-buffered formalin and embedded in paraffin) obtained from Invitrogen were treated according to the manufacturer's instructions with antibodies and detection systems as above for the cultured cells. TMAs were deparaffininzed with the Benchmark XT system.
Single-dimensional Western blot analysis involved electrophoresis of cell lysates prepared as described,15 on NuPAGE 4–12% Bis-Tris gels (Invitrogen). Gels were equilibrated in buffer and electroblotted onto nitrocellulose membranes. Transfer blots were soaked in blocking buffer containing 5% w/v nonfat dry milk in 1× PBS and 0.1% v/v Tween 20, incubated with primary IgY, IgG or IgM antibodies overnight at 4°C. All primary antibodies were diluted 1:1000. Blots were then washed and incubated with HRP (horse radish peroxidase)-conjugated secondary antibodies, either goat anti-chicken IgY (GenWay) or goat anti-mouse IgG + IgM (Abcam), for 1 hr at room temperature. After washing with Tween-PBS, bound antibody was visualized with 3,3′-diaminobenzidine (DAB; Sigma, St. Louis, MO).
Layered peptide array (LPA) analysis
P-FILM Smart Antibody Affinity membranes (20/20 GeneSystems, Rockville, MD) coated with the peptide or protein of interest, were placed within a vacuum plate (Bio-Rad, Hercules, CA). Antibodies were applied to the 96 wells in the plate in duplicates and incubated for 5 min at room temperature. Vacuum was applied for 5 min followed by washing of the membranes in PBS for 5 min, and then incubation with secondary FITC- or Alexa-conjugated, isotype specific antibodies for 30 min at room temperature with shaking, followed by another wash in PBS. Membranes were dried on a filter paper (Whatman, Florham Park, NJ) and scanned on a Typhoon scanner with 520 BP40 and ALEXA filters (Amersham Biosciences, Piscataway, NJ). Images of the membranes were imported to the ImagePro 4.5 analysis software (MediaCybernetics, Bethesda, MD) for analysis. Each membrane included 96 dots. The optical density was calculated by the program for each well in the membrane by marking a circle containing each dot. The optical density was defined according to the following formula: [OD = −Log10(X/256)] with 256 representing the total number of gray levels in the image and X the individual level of gray of each object (each well of the 96 wells for membrane). The measurements were repeated 2 times, for every duplicate well. Thus, a data set of average optical densities for each antibody in the membranes was generated. Data were imported to Microsoft Excel and mean ± standard deviation values were calculated.
For comparative studies, Student's t-test (unpaired) or one-way ANOVA tests (with Bonferroni post test if p < 0.05) were used for statistical analysis. Differences were considered statistically significant if a p value of < 0.05 was achieved.
In fixed cell preparations, chick antibody YXPB-IgY-hHER2/p detected high levels of HER2 protein in HER2-expressing cell line SK-BR-3 compared with low-expressing MCF-7 controls (Fig. 1a). Significant high-level HER2 fluorescence signal was localized to the cell membrane in SK-BR-3 cells as seen in optical sections from deconvolution experiments, whereas only low signal levels were found in the MCF-7 controls.
For comparison, similar experiments with commercial mammalian IgG antibody CB11 (Table I) raised against HER2 were also performed. High HER2 expressing cell line SK-BR-3 showed membrane-limited fluorescence when probed with CB11; with this antibody, MCF-7 cells showed low HER2 signal (Fig. 1b). As performance of mammalian IgG antibody AO485 is considered on a par with CB11 in HER2 immunohistochemistry (IHC) testing, the same experiment was not performed with the AO485 antibody.
For chick antibody YXPB-IgY-hTel/p analysis, model telomerase expression cell lines included A549 (high expression) and IMR90 (very low expression control) cells, respectively. The IgY antibody detected epitopes exclusively within the nucleus in A549 cells, but not in nucleus or cytoplasm of low-expressing IMR90 cells (Fig. 1c). Representative images from stacks (n = 20 sections total) of telomerase signals in A549 and IMR90 cells are illustrated in Figure 2. For A549, cell to cell heterogeneity in total telomerase signal was found among nuclei. Detailed data on distribution and heterogeneity of telomerase expression detected with chick YXPB-IgY-hTel/p antibody will be presented elsewhere.
Commercial mammalian IgG antibody NCL-hTERT (Fig. 1d) showed a lower signal level in telomerase-expressing A549 cells, than the chick antibody. Telomerase-specific IgM NB100–297 signals were not detected in either A549 or IMR90 cells with the quantum dot detection methods (data not shown). Measurements of total Qdot605 fluorescence in 10 cells are shown in Figure 3, quantitating the images in Figure 1.
In these two model cancer biomarker systems, mammalian IgGs and chick IgYs were detected with the same secondary fluorophores (biotinylated anti-isotype antibodies followed by streptavidin-Qdot605 conjugates). However, because of differences in the antigens, the isotypes of the primary and the second antibodies, comparisons are considered relative, not directly quantitative among isotypes.
Immunodetection with quantum dot fluorophores in cultured cells
Empirically, comparing chicken with mammalian antibody in the HER2 model, IgY antibody YXPB-IgY-hHER2/p showed greater total signal for SK-BR-3 than IgG antibody CB11 (Fig. 3, blue bars, 4,131 vs. 2,428 fluorescence intensity units, p = 0.04). The HER2-related IgY and IgG signals for MCF-7 low-expressing control were not statistically different (p = 0.13).
Comparisons of mammalian with avian antibodies for telomerase as target showed chick YXPB-IgY-hTel/p antibody about 4.6-fold greater signal for A549 cells than mammalian NCL-hTERT antibody (Fig. 3, green bars, 3,269 vs. 712 fluorescence units, p = 0.04). Signal differences for IMR90 low expressing control between telomerase-related IgY and IgG were statistically not significant (p = 0.30). These quantitative differences between signals elicited by avian and mammalian antibodies were proportional, high to low signal, in both HER2 and telomerase model systems.
These data suggest that for the antibodies tested, IgY polyclonal antibodies gave greater signal than mammalian antibodies detected with quantum dot fluorophore-labeled secondary antibodies. Differences may arise from the antibody clonality (mono- vs. poly-clonal), the specific isoforms or processed polypeptide detected by each antibody, and the fact that antibodies were raised to different polypeptide regions of the same target molecules (Table I).
To independently determine whether these antibodies detected the appropriate target proteins by molecular weight and abundance in highly expressing cells, polyacrylamide gel electrophoresis (PAGE) followed by Western blots was performed15 (Fig. 4). On the three vertical panels depicting parallel PAGE gels for HER2 (Fig. 4a), CB11 (top panel) detected a faint band of ∼185 kD in cell extracts from expressor SK-BR-3 cells. No band at this molecular weight was detected in similarly prepared extracts of negative control MCF-7 cells. The AO485 anti-HER2 antibody was not evaluated by Western blotting. Chick antibody YXPB-hHER2/p (middle panel) detected a band of ∼185 kD in SK-BR-3 cells that was absent from control MCF-7 cells. The sample loading control for β-actin (antibody ab13,822, Table I) at 42 kD (lowest panel) shows equal amounts of protein lysate were present in each lane.
PAGE/Western blot analysis with anti-telomerase antibodies is shown in the 4 panels of Figure 4b. Neither the commercial IgM antibody NB297–100, nor IgG NCL-hTERT detected signal in cell lines of the telomerase model system (top panel and second from top). Loading controls are shown in the bottom panel. By contrast, the chick telomerase antibody YXPB-IgY-hTel/p detected a visible ∼127 kD band in A549 cells that was absent in IMR90 cells (third panel from top).
Differences in Western blot signal represent different levels of target protein between cell lines. Diaminobenzidine (DAB) detection is semi-quantitative, however the relative protein abundance and approximate size of the targets HER2 and telomerase is consistent with correct detection of the targeted proteins. These data with the immunochemical data above indicate the IgY results are consistent with detection of appropriate target proteins in the cell culture model system, and Western blot bands detected were of appropriate molecular weights. The basis of lack of telomerase Western blot signal in high expression A549 cells detected by commercial antibodies is unknown, although it is well known that antibodies successful in IHC may or may not prove adequate for Western blot experiments.
Quantitative comparisons of IgYs with mammalian antibodies
To further characterize antibody performance, a novel layered peptide array technology (LPA)9 was used. Although the most direct relative performance experiments would be on isotype-matched antibodies generated in response to the identical antigens in various species, a preliminary trend was evaluated by comparing chick IgYs with mammalian antibodies that were commercially available and widely used. Although a comprehensive set of overlapping peptides were not available for these affinity studies,16 a preliminary estimate of relative antibody performance was made with antibodies tested against a dilution series of a limited set of polypeptide antigens by LPA.9 The scope of work presented here precluded re-synthesis of immunogens for all antibodies, although immunogens for the HER2 and telomerase IgYs were available. Therefore, these results are a preliminary comparison among antibodies. The purpose of the LPA work was to collect preliminary data on selected, widely available antibodies with immunogen peptides specifically used to generate the new chick reagents. Immunogen design and sequence will be presented elsewhere.8
LPA data for anti-HER2 reagents (Fig. 5a) include chick IgY antibody (YXPBY-hHER2/p), rabbit IgG antibody (AO485) and mouse IgG isotype antibody (CB11). Antibody dilutions were tested against a polypeptide antigen covalently bound to the proprietary assay membrane.9 All these HER2-specific antibodies tested against the peptide antigen used to raise YXPB-IgG-hHER2/p, were not different from negative control at 0.5–2 μg/ml of antibody (p > 0.05). However, at higher concentrations (8, 16 μg/ml), chick antibody YXPB-IgY-hHER2/h showed greater membrane binding with increase in the amount of antigen peptide bound (at 8, 16 μg/ml, p = 0.01 and 0.004, respectively). The mouse CB11 antibody, which was raised to HER2 (Table I) but not the specific immunogen tested here, also showed activity against this peptide, however, the IgY binding to membrane-bound immunogen was 10–25% higher (p < 0.01). The rabbit antibody AO485 (anti-HER2 IgG) showed no concentration-specific signal increase against this particular peptide. This is not surprising as antibody AO485 was raised against a carboxyterminal intracytoplasmic human HER2 antigen commercially developed for IHC applications (Table I).
Results for the antibodies raised against telomerase polypeptides are shown in Figure 5b. For the IgY, binding increased gradually from 0.5 to 16 μg/ml. However, at most antibody concentrations from 1 to 16 μg/ml, YXPB-IgY-hTel/p showed significantly higher binding signal than IgG (1, 2, 4, 16 μg/ml, p = 0.02, 0.006, 0.002, and 0.006, respectively). At 8 μg/ml, binding of the mammalian and avian antibodies is statistically indistinguishable (p > 0.05), and at 0.5 μg/ml, the IgG appeared to have significantly greater binding. Consistent with the immunochemical data, the signal for the mammalian IgM isotype antibody NB100–297 was weak or absent in LPA.
Quantitation with TMAs
With cell culture results indicating correct targeting of reagents and relative quantitation capabilities for both models, formalin fixed, paraffin embedded patient tumor cores were screened with IgY antibodies in commercially available tissue microarrays (TMAs). Representative images are shown from experiments with quantum dot-detected HER2 IgY in breast cancer patient tumor biopsies with HER2 overexpression (Fig. 6a), with normal HER2 expression (Fig. 6b), and in normal colon controls (Fig. 6c); and telomerase IgY detection of telomerase in biopsies from prostate cancer (Fig. 6d), in benign prostate hyperplasia (BPH; Fig. 6e) and in normal colon controls (Fig. 6f).
Ten cells in each image were randomly selected for quantitation of the levels of IgY-detected signal as above, and these data are represented in the histograms under the tissue section images (Fig. 6). For breast cancer TMAs, overall positive signal intensity was approximately similar to signal detected in cell cultures compared to background and controls. The tumors collectively showed ∼20-fold greater HER2 signal than normal colonic tissue provided in the tissue microarray as detected with IgY and quantum dot imaging. In parallel, prostate tumor tissues collectively showed ∼11-fold overexpression of telomerase nuclear signal compared to BPH.
In the breast cancer TMA, 60 core breast tumor tissues were represented, encompassing both HER2-positive and HER2-negative tumors determined independently by CISH. Double-blind IgY screening here detected a positive signal (above threshold defined by signal in normal colon) in 10 of 60 breast tumors. Independently performed CISH for HER2 gene copy number showed 9 of 60 breast cancer tissue cores had amplified HER2 gene according to TMA supplier. Thus, of the 10 HER2-positive breast tumor cores that expressed high levels of HER2 as detected by IgY HER2 antibody and quantum dot imaging, one was read as negative by CISH. As no clinical data other than CISH result were provided with TMAs, no further analysis of IgY results in these clinical materials was possible.
In a smaller set of prostate tumor TMA cores (n = 20 patients) and parallel TMA cores of BPH, telomerase-positive signals were detected in 20/20 prostate tumor cores. Among these, two prostate tumors had signal levels of 20–60 intensity units and 18 prostate tumors had signal levels of >60 intensity unit levels. Signals in the benign prostatic hyperplasia cores (n = 20 patients) were not above background as defined by the normal colon core included in the TMA.
Clinical data available for prostate tumor patients (patient age, size of tumor, consistency of tumor, cellular differentiation and clinical diagnosis) were compared to IgY imaging results for telomerase. For the 18 prostate tumors for which Gleason Grades were reported, the average and standard deviation of telomerase signal for quantitative telomerase imaging for all tumors (grades 4–10) was 149 ± 40. For those at Gleason Grade 7 and above (n = 14), telomerase signal value was 159 ± 35. Among tumors at Gleason Grades 4, 5 and 6 (n = 4), the telomerase signal value was 96 ± 34.
When telomerase values for prostate tumors (n = 19) were compared with the level of cellular differentiation (well-differentiated, moderate, poor), well differentiated tumors showed an average and standard deviation for telomerase signal value of 145 ± 21 (n = 2). Among moderately differentiated tumors (n = 11), the telomerase value was 133 ± 40. Finally, among poorly differentiated tumors (n = 6), the average telomerase value was 180 ± 8. Like Gleason grading, the trend in the data is lower telomerase index with moderately differentiated tumors, and a higher value among poorly differentiated tumors.
Telomerase quantitation with chick IgY antibodies and quantum dot imaging suggests a trend toward correlation with Gleason Grade and differentiation, however, more work is clearly indicated.
The ability to quantitate cancer biomarkers depends on the uniqueness of interaction of primary reagents with targets. A major drawback of using mammalian IgG antibodies in clinical diagnostics is reactivity with anti-mammalian IgG antibodies, e.g. human anti-mouse IgG antibodies, rheumatoid factor, and the human complement system, which are often present in clinical samples such as serum or plasma, resulting in false positives, high background, or increased interference.
IgY antibodies have a number of intrinsic biochemical advantages over mammalian IgGs (for a complete review, see ref.17). Because of their structural and amino acid sequence characteristics, IgYs do not activate complement. In addition, IgYs do not bind to proteins A and G, to rheumatoid factors, or to cell surface Fc receptor. Consequently, IgY antibodies have been used successfully in a variety of methods in different areas of research, diagnostics, medical application and biotechnology.17 Using IgY in immunoassays can potentially eliminate false positives, and often results in low background and interference.
In addition to the intrinsic biochemical and immunological advantages, IgY has several other attractive advantages in terms of its production.17 IgY antibodies are usually produced using chickens or ducks as the immunization host and their eggs as the sources for antibody isolation. Thus, IgYs usually have enhanced immunogenicity against conserved mammalian proteins because of the phylogenetic distance between donor and recipient organisms.18 Also, IgY antibodies were found to have high affinity or avidity against human proteins.19–21 Moreover, polyclonal IgY antibodies can be produced more quickly and at lower cost.
In this study, we have generated two novel IgY antibodies for fluorescence quantitation of cancer biomarkers HER2 and telomerase. The results presented here indicate that the IgY antibodies are consistent in analytical validation studies with detection of the appropriate targets. The evidence for this comes from the approximate sizes of the proteins detected, expression in both cell culture systems and fixed patient tumors, and subcellular localizations. The results also indicate that compared with mammalian IgGs or IgMs, detection of the cancer biomarkers with IgY antibodies was more sensitive.
The ability to quantitate cancer biomarkers depends on the degree of quantitation possible with the detection system. The method presented here, comparing high and low expressor cell lines by relative intensity of signals, could be considered as relative quantitation. To be truly quantitative, the use of quantifiable references or calibration standards is needed. Also, sample preparation should be consistent and rigorously controlled. In the present study, the cell lines were fixed in zinc formalin but not paraffin embedded. In addition, the use of commercially acquired TMAs, which were prepared by means unknown, renders the method not fully quantitative.
Biologically, the HER2 IgY appeared to detect overexpression in 1 breast tumor that was not found to have the gene amplified by CISH analysis. Also, the chick IgY for HER2 correlated well with CISH in the other tumors (n = 59 patients).
The fact that telomerase remains a controversial cancer biomarker makes the telomerase IgY data of interest and possible significance. Previous recent studies have found no association between telomerase activity or mRNA, and clinical prostate cancer Gleason grade or stage.22 Some prior IHC studies have used a telomerase antibody that detects nucleolin, not telomerase.7 Although not conclusive, the trends in the present study warrant further investigation of a quantitative relationship between IHC-detected telomerase and clinical status of prostate cancer patients and their tumors.
While these preliminary data suggest a difference in telomerase values between tumors of Gleason Grade 6 and below, and tumors of Gleason Grade 7 and above, and between moderate and poorly differentiated tumors, further studies in larger patient populations are warranted to resolve whether this is a biological difference or due to the small numbers of patients in this preliminary study. While general trends are evident in comparisons of telomerase-IgY elicited fluorescence intensity with clinical parameters in this data set, the number of tumors was felt to be insufficient to evaluate these initial results. While it is tempting to speculate on initial specificity and sensitivity of the IgY IHC results for both the breast cancer data and the prostate cancer data, such comparisons will be deferred until a larger clinical cohort can be characterized in greater detail with automated methods.
We demonstrate here the feasibility of detection and measurement of cancer biomarker protein levels at single-cell resolution in limited cell populations of the size that might be collected as specimens for early cancer detection. Here clinical materials consisted of TMAs. However, in a more useful sampling format, clinical body fluids such as blood, sputum, stool, nipple aspirate, or urine all contain cells that could be analyzed by this method for the presence of HER2- or telomerase-expressing cancer cells. Cells from fine needle aspirates, although not considered an early cancer detection screening modality, would also be amenable to analysis as described here. The combination of IgY isotype-specific antibodies, novel quantum dot detection systems,14, 23 digital collection of in-focus fluorescence signal in all focal planes (3D deconvolution), and robotic, programmed high-throughput slide preparation, set the stage for development of an early cancer diagnostic low-cost, high accuracy test platform may be of clinical value. The TMA results demonstrate that the new IgY reagents can be used to generate relative quantitation data for studying clinical populations in fixed clinical histopathology formats.
Certain commercial equipment or materials are identified in this paper in order to specify adequately the experimental procedures. Such identification does not imply recommendation or endorsement by the National Institute of Standards and Technology, nor does it imply that the materials or equipment identified are necessarily the best available for the purpose. Supported in part by NCI-NIST Interagency Agreement Y1-CN-45016 (PI, PEB). HER2 work supported in part by NIST HER2 Standard Reference Material development funds (PEB) for RM 2373, Standard for HER2 Testing. The authors declare that they have no competing financial interests. Drs. Emmert-Buck and Gannot are inventors of layered peptide arrays, a new technology being co-developed by the NIH and 2020 GeneSystems, Inc., and can receive royalty payments through the NIH technology transfer program.
- 82006, attorney docket number 000479. 00163.. IgY antibodies to human telomerase reverse transcriptase. Patent application filed, June 26,
- 20High-affinity antibodies from hen's-egg yolks against human mannose-6-phosphate/insulin-like growth-factor-II receptor (M6P/IGFII-R): characterization and potential use in clinical cancer studies. Int J Cancer 1999; 80: 896–902., , , , , .
- 22Expression of human telomerase reverse transcriptase. Survivin. DD3 and. PCGEM1 messenger. RNA in archival prostate carcinoma tissue. Can J Urol 2006; 13: 2967–74., , , , .